 This study evaluates the efficacy and tolerability of methotrexate in treating E.M.Coo disable lineomorphia subtype, finding that all seven included patients improved with methotrexate therapy within an average of two months to disease inactivity and 16 months to discontinuation of methotrexate. This article was authored by Ploysine Ratanikimacorn and J.C.F.E.L.